NRX PHARMACEUTICALS INC (NRXP)
US6294442099 - Common Stock
NRXP gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. NRXP may be in some trouble as it scores bad on both profitability and health. NRXP has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year NRXP has reported negative net income.
NRXP had a negative operating cash flow in the past year.
NRXP had negative earnings in 4 of the past 5 years.
NRXP had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -456.95%, NRXP is doing worse than 96.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -456.95% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-544.09%
ROA(5y)-329.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NRXP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for NRXP has been increased compared to 1 year ago.
The number of shares outstanding for NRXP has been increased compared to 5 years ago.
Compared to 1 year ago, NRXP has a worse debt to assets ratio.
2.2 Solvency
NRXP has an Altman-Z score of -103.47. This is a bad value and indicates that NRXP is not financially healthy and even has some risk of bankruptcy.
NRXP has a Altman-Z score of -103.47. This is amonst the worse of the industry: NRXP underperforms 94.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -103.47 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 0.20 indicates that NRXP may have some problems paying its short term obligations.
NRXP has a worse Current ratio (0.20) than 97.37% of its industry peers.
A Quick Ratio of 0.20 indicates that NRXP may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.20, NRXP is doing worse than 97.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.2 | ||
| Quick Ratio | 0.2 |
3. Growth
3.1 Past
NRXP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.00%, which is quite impressive.
EPS 1Y (TTM)60%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, NRXP will show a very strong growth in Earnings Per Share. The EPS will grow by 35.02% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y51.55%
EPS Next 2Y39.94%
EPS Next 3Y35.02%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NRXP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NRXP. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as NRXP's earnings are expected to grow with 35.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.94%
EPS Next 3Y35.02%
5. Dividend
5.1 Amount
No dividends for NRXP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NRX PHARMACEUTICALS INC
NASDAQ:NRXP (12/24/2024, 7:28:33 PM)
Premarket: 1.69 +0.12 (+7.64%)1.57
+0.15 (+10.56%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners4.75%
Inst Owner Change97.81%
Ins Owners26.51%
Ins Owner Change4.6%
Market Cap18.98M
Analysts82.22
Price Target32.3 (1957.32%)
Short Float %6.12%
Short Ratio3
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)42.79%
Min EPS beat(2)5.49%
Max EPS beat(2)80.09%
EPS beat(4)3
Avg EPS beat(4)20.91%
Min EPS beat(4)-31.91%
Max EPS beat(4)80.09%
EPS beat(8)5
Avg EPS beat(8)14.6%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.06%
PT rev (3m)2.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-41.48%
EPS NY rev (1m)31.98%
EPS NY rev (3m)32.98%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.04
EYN/A
EPS(NY)-0.17
Fwd EYN/A
FCF(TTM)-0.97
FCFYN/A
OCF(TTM)-0.97
OCFYN/A
SpS0
BVpS-1.56
TBVpS-1.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -456.95% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-544.09%
ROA(5y)-329.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 20% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.2 | ||
| Quick Ratio | 0.2 | ||
| Altman-Z | -103.47 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)220%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.43%
EPS Next Y51.55%
EPS Next 2Y39.94%
EPS Next 3Y35.02%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y38.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y72.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y72.54%
OCF growth 3YN/A
OCF growth 5YN/A